Bicocca Open Archive

Logo unimib boa
BIAGI, ETTORE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.028
AS - Asia 5.502
EU - Europa 4.848
SA - Sud America 782
Continente sconosciuto - Info sul continente non disponibili 429
AF - Africa 131
OC - Oceania 11
Totale 26.731
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.254
SG - Singapore 1.961
CN - Cina 1.280
IT - Italia 807
HK - Hong Kong 741
SE - Svezia 719
RU - Federazione Russa 688
VN - Vietnam 673
CA - Canada 664
DE - Germania 620
BR - Brasile 589
UA - Ucraina 494
IE - Irlanda 464
GB - Regno Unito 302
FR - Francia 209
IN - India 184
FI - Finlandia 143
BD - Bangladesh 115
TR - Turchia 88
KR - Corea 78
AR - Argentina 75
NL - Olanda 74
IQ - Iraq 57
ID - Indonesia 54
MX - Messico 54
AT - Austria 53
ES - Italia 51
BE - Belgio 46
PL - Polonia 46
DK - Danimarca 40
PK - Pakistan 39
ZA - Sudafrica 39
JP - Giappone 38
PH - Filippine 29
SA - Arabia Saudita 29
CO - Colombia 24
EC - Ecuador 24
BG - Bulgaria 22
VE - Venezuela 22
CL - Cile 18
UZ - Uzbekistan 16
TN - Tunisia 14
EG - Egitto 12
JM - Giamaica 12
MY - Malesia 12
NP - Nepal 12
ET - Etiopia 11
IL - Israele 11
IR - Iran 11
RO - Romania 11
CZ - Repubblica Ceca 10
EU - Europa 10
MA - Marocco 10
CR - Costa Rica 9
KE - Kenya 9
UY - Uruguay 9
AE - Emirati Arabi Uniti 8
BO - Bolivia 8
JO - Giordania 8
AU - Australia 7
AZ - Azerbaigian 7
CH - Svizzera 7
KZ - Kazakistan 7
TH - Thailandia 7
TT - Trinidad e Tobago 7
AL - Albania 6
DZ - Algeria 6
NG - Nigeria 6
BY - Bielorussia 5
MU - Mauritius 5
OM - Oman 5
PR - Porto Rico 5
PY - Paraguay 5
RS - Serbia 5
TW - Taiwan 5
AO - Angola 4
GT - Guatemala 4
HN - Honduras 4
KG - Kirghizistan 4
LT - Lituania 4
MN - Mongolia 4
NI - Nicaragua 4
PE - Perù 4
SN - Senegal 4
DO - Repubblica Dominicana 3
GR - Grecia 3
HR - Croazia 3
KW - Kuwait 3
NZ - Nuova Zelanda 3
PA - Panama 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
XK - ???statistics.table.value.countryCode.XK??? 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BH - Bahrain 2
BZ - Belize 2
GA - Gabon 2
Totale 26.284
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.605
Ashburn 1.520
Woodbridge 1.238
Singapore 1.097
Fairfield 876
Houston 824
Hong Kong 728
Chandler 717
Wilmington 694
San Jose 546
Jacksonville 524
Toronto 463
Dublin 455
Seattle 388
Frankfurt am Main 350
Cambridge 337
Dearborn 316
Milan 271
New York 253
Beijing 220
Santa Clara 206
Princeton 197
Council Bluffs 195
Ho Chi Minh City 191
Los Angeles 178
Chicago 172
Hanoi 135
Nanjing 135
Hefei 127
The Dalles 114
Dallas 93
Shanghai 92
Lawrence 85
Lachine 84
Lauterbourg 81
Altamura 68
Seoul 68
Buffalo 65
Boardman 61
Dong Ket 60
Moscow 60
Rome 60
São Paulo 57
Vienna 49
San Diego 48
Helsinki 45
Brussels 44
Orem 42
Montreal 39
Nanchang 38
Warsaw 37
Tianjin 35
London 34
Andover 33
Denver 33
Guangzhou 33
Lissone 33
Atlanta 31
Da Nang 31
Shenyang 31
Fremont 30
Brooklyn 28
Hebei 27
Mountain View 27
Phoenix 27
Stockholm 27
Columbus 26
Rio de Janeiro 26
Hangzhou 25
Munich 25
Baghdad 24
Huizen 23
Philadelphia 23
Amsterdam 22
Tokyo 22
Changsha 21
Zhengzhou 21
Chennai 20
Plovdiv 20
Salt Lake City 19
Boston 18
Jakarta 18
Jinan 18
Ningbo 18
Ottawa 18
Poplar 18
Detroit 17
Manchester 17
Mexico City 17
San Francisco 17
Haiphong 16
Jiaxing 16
Brasília 15
Figino 15
Turin 15
Washington 15
Falls Church 14
Johannesburg 14
Kocaeli 14
Las Vegas 14
Totale 17.449
Salva come PNG Salva come JPEG
Nome #
Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients 510
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 495
Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation 492
Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies 460
Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System 447
Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories 444
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia 443
GMP-grade preparation of biomimetic scaffolds with osteo-differentiated autologous mesenchymal stromal cells for the treatment of alveolar bone resorption in periodontal disease 432
Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia 413
Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring 405
Full GMP-Compliant Validation of Bone Marrow-Derived Human CD133+ Cells as Advanced Therapy Medicinal Product for Refractory Ischemic Cardiomyopathy 405
Interleukin-17-producing t-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation 388
Immunotherapy of acute leukemia by chimeric antigen receptormodified lymphocytes using an improved Sleeping Beauty transposon platform 375
TNFRSF13C (BAFFR) positive blasts persist after early treatment and at relapse in childhood B-cell precursor acute lymphoblastic leukaemia 369
Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase 1 Study On 47 Adult and Pediatric Patients 364
T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy 363
Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia 359
Stable Expression Of Chimeric Antigen Receptors (CARs) By Sleeping Beauty-Mediated Gene Transfer and Efficient Expansion Of Leukemia-Specific Cytokine-Induced Killer (CIK) Cells 357
Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. 355
Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population 355
Characterization of Plated Lysate Cultured Mesenchymal Stromal Cells and Their Potential Use in Tissue-Engineered Osteogenic Devices for the Treatment of Bone Defects 346
Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation 329
Exploration of the lysis mechanisms of leukaemic blasts by chimaeric T-cells 326
Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy 323
Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia 315
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: A phase I study 314
Cytokine Induced Killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors 312
Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors 310
Chimeric Antigen Receptors against CD33/CD123 antigens efficiently target primary Acute Myeloid Leukemia cells in vivo 309
Chimeric T-cell receptors: New challenges for targeted immunotherapy in hematologic malignancies 307
Bath PUVA therapy in pediatric patients with drug-resistant cutaneous graft-versus-host disease 306
Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. 303
Immunosuppression does not affect human bone marrow mesenchymal stromal cell efficacy after transplantation in traumatized mice brain 303
GMP-based CD133(+) cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy 303
Donor-derived CD19-targeted T cells in allogeneic transplants 301
Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives 299
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia 290
Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor 290
Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient 287
Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia 287
Upregulation of adhesion molecules on leukemia targets improves the efficacy of cytotoxic T cells transduced with chimeric anti-CD19 receptor 286
Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells 285
Characterization of migratory activity and cytokine profile of helper and cytotoxic CMV-specific T-cell lines expanded by a selective peptide library 284
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes 282
A life-threatening paediatric case of acute autoimmune haemolytic anaemia (AIHA) successfully cured by plasma-exchange and combined immunosuppressive treatment 282
Development of an alveolar bone regeneration protocol with mesenchyl stem cells for the therapy of severe bone resorption in periodontal disease 277
T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells 273
Targeting of Acute Myeloid Leukemia by Cytokine-Induced Killer Cells Redirected with a Novel CD123-Specific Chimeric Antigen Receptor 273
Allogeneic mesenchymal stem cell infusion for the stabilization of focal segmental glomerulosclerosis 270
TBI, etoposide and cyclophosphamide as a promising conditioning regimen for BMT in childhood ALL in second remission 269
Long-term effects of bone marrow transplantation on dental status in children with leukaemia 268
Isolation of monocytes from leukapheretic products for large-scale GMP-grade generation of cytomegalovirus-specific T-cell lines by means of an automated elutriation device 267
Cell-based strategies to manage leukemia relapse: Efficacy and feasibility of immunotherapy approaches 267
Febrile complications in the first 100 days after bone marrow transplantation in children: a single center's experience 266
Failure of interferon-γ pre-treated mesenchymal stem cell treatment in a patient with crohn's disease 266
The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs 260
Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine 256
Antigen-induced regulatory T cells 253
CD40 activation of BCP-ALL cells generates 11L-10-producing, 11L-12-defective APCs that induce allogeneic T-cell anergy 250
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. 245
Estudio experimental sobre la utilización de células madre humanas en la terapia de los defectos periodontales: resultados preliminares 244
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia 244
PTX3 as a potential novel tool for the diagnosis and monitoring of pulmonary fungal infections in immuno-compromised pediatric patients. 242
Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia 240
Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells 237
Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes 236
Chimeric Antigen Receptor for Specific Targeting of Acute Myeloid Leukemia 236
Intrathecal chemotherapy with antineoplastic agents in children 235
Role of early diagnosis for a noninvasive treatment of pulmonary thromboembolism in leukemic children 232
Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis 226
Efficient lentiviral transduction of primary human acute myelogenous and lymphoblastic leukemia cells 222
Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells 221
A persistent severe autoimmune hemolytic anemia despite apparent direct antiglobulin test negativization 219
Mechanical and infective central venous catheter-related complications: a prospective non-randomized study using Hickman and Groshong catheters in children with hematological malignancies 216
Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. Mol Cancer 215
Prolonged extracorporeal membrane oxygenation therapy for severe acute respiratory distress syndrome in a child affected by rituximab-resistant autoimmune hemolytic anemia: A case report 215
CD40 ligand-stimulated B cell precursor leukemic cells elicit interferon-gamma production by autologous bone marrow T cells in childhood acute lymphoblastic leukemia 211
New findings about the Interplay among Clarithromycin, Immune and Central Nervous Systems 211
In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia 210
LONG TERM SURVIVAL AND EFFICACY OF HUMAN BONE MARROW MESENCHYMAL STEM CELLS IN TRAUMATIZED MICE BRAIN IS NOT DEPENDENT ON IMMUNOSUPPRESSIVE TREATMENT. 201
A Phase 1/2 Study of Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 in Patients With High-risk Neuroblastoma 197
In Vitro Comparison of Three Different Chimeric Receptor-modified Effector T-cell Populations for Leukemia Cell Therapy 197
From Bone Marrow Transplantation to Cellular Therapies: Possible therapeutic strategies in managing autoimmune disorders 197
New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future 195
Basic biology and clinical application of multipotent mesenchymal stromal cells: from bench to bedside 188
Effectiveness of extracorporeal photochemotherapy in treating long-term refractory chronic graft-versus-host disease 187
Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells 182
Mesenchymal stem/stromal cells: a new "cells as drugs" paradigm. Efficacy and critical aspects in cell therapy 178
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor 176
Long term efficacy of human bone marrow mesenchymal stem cells in traumatized mice brain is not affected by immunosuppressive treatment 174
Phase I Trial of Vaccination With Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 and Lymphotactin 172
LONG TERM EFFICACY OF HUMAN BONE MARROW MESENCHYMAL STEM CELLS IN TRAUMATIZED MICE BRAIN IS NOT AFFECTED BY IMMUNOSUPPRESSIVE TREATMENT. 166
LONG TERM EFFICACY OF HUMAN BONE MARROW MESENCHYMAL STEM CELLS IN TRAUMATIZED MICE BRAIN IS NOT AFFECTED BY IMMUNOSUPPRESSIVE TREATMENT. 134
Low-Dose Lenalidomide Improves CAR-Based Immunotherapy In CLL By Reverting T-Cell Defects In Vivo 105
Totale 26.731
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.872
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.872
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022982 0 0 0 106 71 68 58 66 138 134 98 243
2022/20232.350 271 730 195 222 136 353 24 149 170 6 68 26
2023/20241.345 44 38 61 55 198 347 263 62 110 8 30 129
2024/20252.935 182 328 134 139 252 74 137 116 377 471 236 489
2025/20267.869 780 466 503 844 999 445 960 392 707 686 580 507
2026/20271.516 186 286 693 351 0 0 0 0 0 0 0 0
Totale 26.731